In the past week, RNAZ stock has gone up by 55.41%, with a monthly gain of 44.05% and a quarterly surge of 52.67%. The volatility ratio for the week is 21.01%, and the volatility levels for the last 30 days are 13.88% for TransCode Therapeutics Inc The simple moving average for the past 20 days is 61.69% for RNAZ’s stock, with a -95.10% simple moving average for the past 200 days.
Is It Worth Investing in TransCode Therapeutics Inc (NASDAQ: RNAZ) Right Now?
Company’s 36-month beta value is -0.23.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RNAZ is 6.54M, and currently, short sellers hold a 0.28% ratio of that floaft. The average trading volume of RNAZ on May 07, 2024 was 534.22K shares.
RNAZ) stock’s latest price update
TransCode Therapeutics Inc (NASDAQ: RNAZ)’s stock price has soared by 15.81 in relation to previous closing price of 0.81. Nevertheless, the company has seen a gain of 55.41% in its stock price over the last five trading days. GlobeNewsWire reported 2024-03-06 that BOSTON, March 06, 2024 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that its Chief Scientific Officer, Zdravka Medarova, Ph.D., will present at this year’s RNA Leaders Europe Congress scheduled to take place March 12-14 in Basel, Switzerland.
RNAZ Trading at 46.90% from the 50-Day Moving Average
After a stumble in the market that brought RNAZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.70% of loss for the given period.
Volatility was left at 13.88%, however, over the last 30 days, the volatility rate increased by 21.01%, as shares surge +41.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +27.41% upper at present.
During the last 5 trading sessions, RNAZ rose by +49.05%, which changed the moving average for the period of 200-days by -99.05% in comparison to the 20-day moving average, which settled at $0.5968. In addition, TransCode Therapeutics Inc saw -85.69% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RNAZ starting from Dudley Robert Michael, who purchase 98,000 shares at the price of $0.51 back on Sep 28 ’23. After this action, Dudley Robert Michael now owns 180,262 shares of TransCode Therapeutics Inc, valued at $49,980 using the latest closing price.
Fitzgerald Thomas A, the Chief Financial Officer of TransCode Therapeutics Inc, purchase 49,350 shares at $0.51 during a trade that took place back on Sep 28 ’23, which means that Fitzgerald Thomas A is holding 56,318 shares at $25,168 based on the most recent closing price.
Stock Fundamentals for RNAZ
The total capital return value is set at -11.56. Equity return is now at value -759.85, with -290.74 for asset returns.
Based on TransCode Therapeutics Inc (RNAZ), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at -40.11. The debt to equity ratio resting at 0.27. The interest coverage ratio of the stock is 686.65.
Currently, EBITDA for the company is -18.9 million with net debt to EBITDA at 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.28.
Conclusion
In a nutshell, TransCode Therapeutics Inc (RNAZ) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
